Somatuline Depot (lanreotide prolonged-release subcutaneous) / Teijin, Ipsen 
Welcome,         Profile    Billing    Logout  

7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
2013-003998-10: A clinical trial investigating the effect of Lanreotide on reducing fistula output in patients with high output enterocutaneous fistula

Ongoing
3/4
40
Europe
Lanreotide autosolution, BIM 23014, Solution for injection/infusion, Somatuline AutoSolution 120 mg
Academic medical center, Academic medical center, Ipsen farmaceuticals
All adult patients with a small bowel fistula with an output > 500ml/day or a an enterostomy with an output > 1500ml/day after gastro-intestinal, abdominal wall surgery. Randomization is possible if patients are at least 4 weeks postoperative and had at least 2 weeks of standard care (loperamide, codeine, PPI)., a highoutput pathway between intestine and the skin, either created by a surgeon or spontaneous after complicated surgery, Diseases [C] - Digestive System Diseases [C06]
 
 
2022-000507-12: A randomized, controlled, open-label study of RYZ101 compared with standard of care therapy in subjects with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following 177Lu SSA therapy Ensayo aleatorizado, controlado y abierto de RYZ101 frente al tratamiento habitual en sujetos con tumores neuroendocrinos gastroenteropancreáticos bien diferenciados SSTR+, avanzados e inoperables, que hayan progresado tras tratamiento con 177Lu SSA.

Not yet recruiting
3
288
Europe
RYZ101, Sunitinib, RYZ101, Sunitinib, L01XE04, Solution for injection, Tablet, Capsule, hard, Powder and solvent for suspension for injection, Solution for injection in pre-filled syringe, Everolimus Zentiva 5mg Tabletten, Szunitinib Mylan 12,5 mg, Sandostatin® LAR®- Monatsdepot 30 mg powder and solvent for suspension for injection, SOMATULINE AUTOGEL 120 mg solution for injection in a pre-filled syringe, Szunitinib Sandoz 12,5 mg
RayzeBio, Inc., RayzeBio, Inc.
gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, Diseases [C] - Cancer [C04]
 
 
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
SORENTO, NCT05050942 / 2021-000849-40: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET

Active, not recruiting
3
332
Europe, Canada, US, RoW
CAM2029, Octreotide LAR, Lanreotide ATG
Camurus AB, Camurus AB
Gastro-enteropancreatic Neuroendocrine Tumor
12/25
12/27
LAMPARA, NCT03946527: LAnreotide in Metastatic Pheochromocytoma / PARAganglioma

Active, not recruiting
2
10
US
Lanreotide, Somatuline Depot
Antonio Fojo, Ipsen
Paraganglioma, Pheochromocytoma
03/26
03/26
OXTEND-01, NCT05364944: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Terminated
1
20
Europe, RoW
Debio 4126, Sandostatin LAR, Octreotide acetate, Somatuline ATG, Lanreotide acetate
Debiopharm International SA
Acromegaly, GEP-NET
10/24
12/24
NCT05431803: Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Completed
N/A
129
RoW
Ipsen
Acromegaly
12/24
12/24

Download Options